Motoi Suzuki, M.D., MSc. PHDC., Ph.D.
Address: Toyama 1-23-1, Shinjuku-ku, Tokyo
162-9640, JAPAN
Tel: +81-3-5285-1111
E-mail: mosuzuki@niid.go.jp

Current position:-Director, Center for Surveillance, Immunization, and Epidemiologic Research, National
Institute of Infectious Diseases, Tokyo, Japan-Visiting Professor, Department of Infectious Disease Epidemiology, Tohoku University Schoolof Medicine, Sendai-Visiting Professor, School of Tropical Medicine and Global Health, Nagasaki University,Nagasaki

Specialities:
Infectious disease epidemiology, Vaccine-preventable diseases

Education:
Nagasaki University Graduate School of Biomedical Sciences, Ph.D., 2014
London School of Hygiene and Tropical Medicine, MSc. of Public Health in DevelopingCountries, 2009
Tohoku University School of Medicine, M.D., 1996

Positions and employment:
Jul 2018-Mar 2019

Associate Professor, Department of Clinical Medicine,
Institute of Tropical Medicine, Nagasaki University

Dec 2009-Jun 2018

Assistant Professor, Department of Clinical Medicine,
Institute of Tropical Medicine, Nagasaki University

Jul 2006-Aug 2008

Assistant Professor, Vietnam Project,
Center for International Collaborative Research, Nagasaki University,Nha Trang, Vietnam
Jul 2005-Jun 2006

Staff Physician, Chikamori Hospital, KochiOct 2003-Apr 2005

Staff Physician, Inoue Hospital, Nagasaki

Dec 2002-Jan 2003

Staff Physician, Nagasaki University Hospital, Nagasaki

Dec 2000-Nov 2002 Staff Physician, Nijigaoka Hospital, Nagasaki
Mar 2000-Nov 2000

Staff Physician, Nomozaki Town Hospital, Nagasaki

Apr 1999-Feb 2000

Staff Physician, Nagasaki University Hospital, Nagasaki

Apr 1997-Mar 1999

Junior Resident, Katta General Hospital, Shiroishi

Selected peer-reviewed publications:1.

Kinoshita R, Sassa M, Otake S, et al. Impact of airline network on the global importation risk of mpox, 2022.
Epidemiol Infect. 2023 Mar 21;151:e60.

2.

Maeda H, Saito N, Igarashi A, et al. Effectiveness of mRNA COVID-19 vaccines against symptomatic SARSCoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine
effectiveness real-time surveillance for SARS-CoV-2 (VERSUS). Expert Rev Vaccines. 2023 JanDec;22(1):288-298.

3.

Imamura T, Watanabe A, Serizawa Y, et al. Transmission of COVID-19 in Nightlife, Household, and HealthCare Settings in Tokyo, Japan, in 2020. JAMA Netw Open. 2023 Feb 1;6(2):e230589.

4.

Arashiro T, Arai S, Kinoshita R, et al. National seroepidemiological study of COVID-19 after the initial rolloutof vaccines: Before and at the peak of the Omicron-dominant period in Japan. Influenza Other Respir
Viruses. 2023 Feb 1;17(2):e13094.

5.

Kobayashi Y, Arashiro T, Otsuka M, et al. Replacement of SARS-CoV-2 strains with variants carrying N501Yand L452R mutations in Japan: an epidemiological surveillance assessment. Western Pac Surveill
Response J. 2022 Sep 16;13(3):1-10.

6.

Kayano T, Sasanami M, Kobayashi T, et al. Number of averted COVID-19 cases and deaths attributable toreduced risk in vaccinated individuals in Japan. Lancet Reg Health West Pac. 2022 Nov;28:100571.

7.

Arashiro T, Arima Y, Muraoka H, et al. Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against
Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During DeltaDominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study(Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study). Clin
Infect Dis. 2023 Feb 8;76(3):e108-e115.

8.

Hayashi K, Kayano T, Anzai A, et al. Assessing Public Health and Social Measures Against COVID-19 inJapan From March to June 2021. Front Med (Lausanne). 2022 Jul 12;9:937732.

9.

Ko YK, Kinoshita R, Yamauchi M, et al. Impact of the Coming-of-Age Day and ceremony on the risk ofSARS-CoV-2 transmission in Japan: A natural-experimental study based on national surveillance data.
Influenza Other Respir Viruses. 2022 Nov;16(6):1026-1032.

10. Ko YK, Murayama H, Yamasaki L, et al. Age-Dependent Effects of COVID-19 Vaccine and of Healthcare
Burden on COVID-19 Deaths, Tokyo, Japan. Emerg Infect Dis. 2022 Sep;28(9):1777-1784.
11. Arashiro T, Arima Y, Stucky A, et al. Social and Behavioral Factors Associated with Lack of Intent toReceive COVID-19 Vaccine, Japan. Emerg Infect Dis. 2022 Sep;28(9):1909-1910.
12. Saito N, Solante RM, Guzman FD, et al. A prospective observational study of community-acquired
bacterial bloodstream infections in Metro Manila, the Philippines. PLoS Negl Trop Dis. 2022 May
25;16(5):e0010414.
13. Maeda H, Saito N, Igarashi A, et al. Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines
Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Delta
Variant Epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS). Clin
Infect Dis. 2022 Nov 30;75(11):1971-1979.
14. Onozuka D, Tanoue Y, Nomura S, et al. Reduced mortality during the COVID-19 outbreak in Japan, 2020:
a two-stage interrupted time-series design. Int J Epidemiol. 2022 Feb 18;51(1):75-84.
15. Maeda H, Sando E, Toizumi M, et al. Epidemiology of Coronavirus Disease Outbreak amongCrewmembers on Cruise Ship, Nagasaki City, Japan, April 2020. Emerg Infect Dis. 2021 Sep;27(9):22512260.